Na maua e Glenmark Pharmaceuticals Limited le faʻatagaga mai le faʻatonuina o fualaau faʻasaina Initia, Drug Controller General o Initia (DCGI), e faʻatautaia se faʻataʻitaʻiga faʻataʻitaʻi o le Vaega 1 o lana tamaʻi mole mole, GRC 54276, o le hematopoietic progenitor kinase 1 (HPK1) inhibitor. GRC 54276 o se tasi o le tele o molelaula fou mai Glenmark's resident, Innovative Medicines Group, faʻauluuluga e Dr. Nikhil Amin, Ofisa Sili Scientific, faʻapitoa i le atinaʻeina o faʻalapotopotoga mole mole mo le ogaoga o manaʻoga faafomaʻi e leʻi ausia. O le HPK1 o se faʻatonuga autu o le T cell, B cell ma le dendritic cell-mediated immune responses, lea e faʻaleleia ai le puipuiga o le antitumor e ala i le faʻagaoioia ma le faʻaogaina o sela T. O le GRC 54276 ua fa'aalia ai le mafai ona fasiotia le tumo i su'esu'ega fa'apitoa e pei o se sui e tasi ma fa'apea fo'i i le tu'ufa'atasia ma inhibitors siaki, ma avea ai ma fa'amuamua maualuga ile immuno-oncology.

O le suʻesuʻega o le a iloiloina le saogalemu ma le gafatia o le GRC 54276 e pei o se monotherapy, faʻapea foʻi ma faʻatasi ma faʻamaʻi siaki i tagata mamaʻi maʻi maʻi toto maualuga ma Hodgkin's lymphoma. Glenmark o le a amataina le Vaega 1 faʻataʻitaʻiga faʻataʻitaʻi i Initia ia Iuni 2022, ma fuafua foi e faila se IND i le US ma Talosaga Faʻataʻitaʻiga Faʻataʻitaʻi i Europa e amata ai se polokalame suʻesuʻega faʻapitoa i le lalolagi atoa.

“O le taumafaiga a Glenmark o le tu'uina atu lea o fofo fa'afoma'i fou i ona vaega autu o togafitiga. Matou te fiafia ona o le matou ulua'i mole mole mai le 'Innovative Medicines Group' fou na fausia i totonu o Glenmark ua maua le fa'atagaga mai le fa'atonu o vaila'au fa'asaina a Initia e amata ai se fa'ata'ita'iga ile Vaega 1. O lenei mea e faʻamalosia ai le faʻatupulaia o gafatia o Glenmark i suʻesuʻega faʻafomaʻi fou ma o se laʻasaga latalata i le tuʻuina atu o vaifofo atoatoa mo togafitiga o le kanesa, "o le tala lea a Glenn Saldanha, Taitaifono & Pule Faatonu, Glenmark Pharmaceuticals Limited.

OA MEA E AVEA MAI LENEI TUSI:

Glenmark o le a amataina le Vaega 1 faʻataʻitaʻiga faʻataʻitaʻi i Initia ia Iuni 2022, ma fuafua foi e faila se IND i le US ma Talosaga Faʻataʻitaʻiga Faʻataʻitaʻi i Europa e amata ai se polokalame suʻesuʻega faʻapitoa i le lalolagi atoa.
O le GRC 54276 ua fa'aalia ai le mafai ona fa'amaoti le tumo i su'esu'ega fa'apitoa e pei o se sui e to'atasi ma fa'apea fo'i ma fa'atasi ma fa'agata siaki, ma avea ai ma fa'amuamua maualuga ile immuno-oncology.
Na maua e le Glenmark Pharmaceuticals Limited le faʻatagaga mai le faʻatonuina o fualaau faʻasaina Initia, Drug Controller General o Initia (DCGI), e faʻatautaia se faʻataʻitaʻiga faʻataʻitaʻiga o le Vaega 1 o lana tamaʻi mole, GRC 54276, o le hematopoietic progenitor kinase 1 (HPK1) inhibitor.